Lead Product(s) : HQP1351
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Partnership
PharmaBlock Enters Strategic Partnership with Ascentage Pharma
Details : Ascentage's lead drug, HQP1351, is developed to treat drug-resistant chronic myeloid leukemia. PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and fu...
Product Name : HQP1351
Product Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : HQP1351
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Guangzhou Healthquest Pharma has submitted a NDA to the Center for Drug Evaluation of China National Medical Products Administration for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia and accelerated phase ...
Product Name : HQP1351
Product Type : Small molecule
Upfront Cash : Not Applicable
June 18, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA
Details : HQP1351 is the first 3rd generation BCR-ABL inhibitor developed in China targeting drug-resistant CML. A pivotal Phase II study is currently under way to test HQP1351. Ascentage plans to file an NDA.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2020
Reset All
